Within the pharmaceutical industry, an immense pressure exists to progress potential therapeutic candidates through the pipeline quicker than ever before. With pharmaceutical laboratories being on the front line of drug development, the pressure for lab leaders to optimize the speed and efficiency of their operations is a core elemental factor of the larger picture. When medicines have the potential to address critical unmet medical needs, the pharmaceutical laboratory needs to speed discovery and deliver.

Drug discovery, development and delivery: a timeline

1. Drug Discovery
   - Pre-clinical: Molecules are identified and evaluated for potential therapeutic benefit.
   - Pre-clinical: Molecules then undergo more rigorous testing.
   - Clinical: Molecules must prove their safety before being tested on humans.
   - Clinical: Molecules then undergo efficacy studies.
   - Approval Review: Data from these studies is submitted to regulatory bodies.
   - Approval Review: Regulatory authorities decide whether the drug can proceed.
   - Approval: The drug is approved for marketing.

2. Clinical
   - Phase I: Safety and tolerability testing.
   - Phase II: Efficacy testing.
   - Phase III: Comparative efficacy testing.
   - Phase IV: Post-marketing surveillance.

3. Regulatory
   - Clinical trials: Data from these trials is submitted to regulatory bodies.
   - Approval Review: Regulatory authorities decide whether the drug can proceed.
   - Approval: The drug is approved for marketing.

What drives productivity pressures in pharmaceutical laboratories?

Increasing sample numbers

Laboratories are already employing strategies to be successful in this time-driven landscape, with many now turning to instrument providers to help them take this to the next level. Laboratories are already employing strategies to be successful in this time-driven landscape, with many now turning to instrument providers to help them take this to the next level.

Key facts

- Achieving quicker results is the #1 concern for pharmaceutical laboratories.
- 83% of lab leaders find that current methods require optimization.
- The sample size usually
- 70% of lab leaders say one of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.

One of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.

The Pharma Lab Leaders Survey

Agilent Technologies partnered with market research company Frost & Sullivan in 2019 to understand the challenges faced by laboratories in the global pharmaceutical and healthcare industry, and how they are addressing these challenges.

Who was surveyed?

Agilent Technologies partnered with market research company Frost & Sullivan in 2019 to understand the challenges faced by laboratories in the global pharmaceutical and healthcare industry, and how they are addressing these challenges.

From which countries?

The Pharma Lab Leaders Survey

Agilent Technologies partnered with market research company Frost & Sullivan in 2019 to understand the challenges faced by laboratories in the global pharmaceutical and healthcare industry, and how they are addressing these challenges.

Who was surveyed?

Agilent Technologies partnered with market research company Frost & Sullivan in 2019 to understand the challenges faced by laboratories in the global pharmaceutical and healthcare industry, and how they are addressing these challenges.

What is new?

Agilent Technologies partnered with market research company Frost & Sullivan in 2019 to understand the challenges faced by laboratories in the global pharmaceutical and healthcare industry, and how they are addressing these challenges.

Nearing 20 years

By reaching out and engaging with the community, Agilent Technologies has been able to work with many new instrument providers to help them take this to the next level.

Cutting-edge solutions

By reaching out and engaging with the community, Agilent Technologies has been able to work with many new instrument providers to help them take this to the next level.

Ongoing challenges

By reaching out and engaging with the community, Agilent Technologies has been able to work with many new instrument providers to help them take this to the next level.

Optimizing Pharmaceutical Laboratory Efficiency and Productivity

By reaching out and engaging with the community, Agilent Technologies has been able to work with many new instrument providers to help them take this to the next level.

Lab workflow

Drug discovery

Promoting efficiency to improve lab productivity and economics

The Pharma Lab Leaders Survey tells us that:

1. 83% of lab leaders find that current methods require optimization.
2. 70% of lab leaders say one of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.
3. 65% of lab leaders would welcome new innovations to increase laboratory efficiency.
4. 80% of lab leaders say one of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.
5. 70% of lab leaders say one of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.
6. 65% of lab leaders would welcome new innovations to increase laboratory efficiency.
7. 80% of lab leaders say one of the most common strategies they are employing to improve productivity is to adopt a positive, proactive approach to improving documentation of the data they generate and the processes they employ.

By reaching out and engaging with the community, Agilent Technologies has been able to work with many new instrument providers to help them take this to the next level.

© Agilent

This information is subject to change without notice and does not represent a commitment on the part of Agilent Technologies. Agilent Technologies shall not be responsible for any errors or omissions in the information provided herein, nor for the results obtained from use of this information.

For more information, visit www.agilent.com/chem/lableaders.